MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive DSO Ratio 2011-2026 | ARAV
Annual DSO Ratio Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 16.8 | 192 | 161 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 192 | 16.8 | 123 |
Quarterly DSO Ratio Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 55.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.2 | 55.2 | 55.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
258 | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
114 | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Cocrystal Pharma
COCP
|
101 | $ 1.51 | 48.04 % | $ 17 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
88.9 | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
60.7 | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
Amgen
AMGN
|
81.2 | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
185 | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 59.6 | -2.45 % | $ 121 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
BioCryst Pharmaceuticals
BCRX
|
55.1 | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cellectis S.A.
CLLS
|
94.5 | $ 3.41 | 1.19 % | $ 116 M |  France |
 |
Biogen
BIIB
|
50.7 | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axon Enterprise
AXON
|
134 | $ 412.81 | -2.54 % | $ 31.3 B | USA |